Optimizing Immunotherapy Selection in Advanced or Metastatic Melanoma: Balancing Efficacy and Safety Across Practice Settings

Panelists discuss how the treatment paradigm for melanoma has evolved to favor upfront dual checkpoint blockade over targeted therapy, except in specific cases where rapid response is needed for symptomatic patients with high LDH.

Panelists discuss how the combination immunotherapy approach is superior to monotherapy for most melanoma patients, with specific exceptions such as desmoplastic melanoma where monotherapy shows remarkably high response rates.